Log in

NYSE:PROF - Profound Medicl Stock Price, Forecast & News

$14.49
-0.23 (-1.56 %)
(As of 02/28/2020 06:58 AM ET)
Today's Range
$13.65
Now: $14.49
$14.86
50-Day Range
$9.89
MA: $15.02
$19.70
52-Week Range
$5.00
Now: $14.49
$20.60
Volume65,000 shs
Average Volume82,285 shs
Market Capitalization$220.90 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Profound Medical Corp. operates as a medical technology company focuses on magnetic resonance guided ablation procedures in Canada, Germany, and Finland. It is developing a treatment to ablate the prostate gland in prostate cancer patients, treatment of uterine fibroids and nerves, and palliative pain treatment for patients with metastatic bone disease. The company is headquartered in Mississauga, Canada.

Industry, Sector and Symbol

Industry Industrial Metals & Minerals
Sub-IndustryN/A
SectorBasic Materials
CUSIPN/A
CIKN/A
Phone647-476-1350

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees64
Market Cap$220.90 million
Next Earnings Date3/3/2020 (Confirmed)
OptionableNot Optionable

Receive PROF News and Ratings via Email

Sign-up to receive the latest news and ratings for PROF and its competitors with MarketBeat's FREE daily newsletter.


Profound Medicl (NYSE:PROF) Frequently Asked Questions

What is Profound Medicl's stock symbol?

Profound Medicl trades on the New York Stock Exchange (NYSE) under the ticker symbol "PROF."

When is Profound Medicl's next earnings date?

Profound Medicl is scheduled to release their next quarterly earnings announcement on Tuesday, March 3rd 2020. View Earnings Estimates for Profound Medicl.

What guidance has Profound Medicl issued on next quarter's earnings?

Profound Medicl issued an update on its FY 2019 Pre-Market earnings guidance on Friday, January, 10th. The company provided EPS guidance of for the period. The company issued revenue guidance of $5.4-5.4 million.

What is the consensus analysts' recommendation for Profound Medicl?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Profound Medicl in the last year. There are currently 1 buy rating and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Strong Buy." View Analyst Ratings for Profound Medicl.

Has Profound Medicl been receiving favorable news coverage?

Headlines about PROF stock have been trending extremely negative on Friday, according to InfoTrie Sentiment Analysis. InfoTrie rates the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Profound Medicl earned a news impact score of -4.2 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the next few days. View News Stories for Profound Medicl.

Who are some of Profound Medicl's key competitors?

What other stocks do shareholders of Profound Medicl own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Profound Medicl investors own include BCE (BCE), IBM (IBM), Gilead Sciences (GILD), Huntington Bancshares (HBAN), Methanex (MEOH), PacWest Bancorp (PACW), People's United Financial (PBCT), Pattern Energy Group (PEGI), Walgreens Boots Alliance (WBA) and AbbVie (ABBV).

Who are Profound Medicl's key executives?

Profound Medicl's management team includes the folowing people:
  • Dr. Arun Swarup Menawat, CEO & Director (Age 64)
  • Mr. Aaron Davidson, CFO & Sr. VP of Corp. Devel. (Age 51)
  • Mr. Stephen Kilmer, Investor Relations

Who are Profound Medicl's major shareholders?

Profound Medicl's stock is owned by many different of retail and institutional investors. Top institutional investors include FIL Ltd (6.40%), Gagnon Securities LLC (4.57%), Gagnon Advisors LLC (1.53%), Royce & Associates LP (1.28%), Renaissance Technologies LLC (0.08%) and Bank of Montreal Can (0.07%).

Which major investors are buying Profound Medicl stock?

PROF stock was purchased by a variety of institutional investors in the last quarter, including FIL Ltd, Gagnon Securities LLC, Gagnon Advisors LLC, Royce & Associates LP, Renaissance Technologies LLC, Bank of Montreal Can and Bank of America Corp DE.

How do I buy shares of Profound Medicl?

Shares of PROF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Profound Medicl's stock price today?

One share of PROF stock can currently be purchased for approximately $14.49.

How big of a company is Profound Medicl?

Profound Medicl has a market capitalization of $220.90 million. Profound Medicl employs 64 workers across the globe.View Additional Information About Profound Medicl.

What is Profound Medicl's official website?

The official website for Profound Medicl is http://www.profoundmedical.com/.

How can I contact Profound Medicl?

The company can be reached via phone at 647-476-1350.


MarketBeat Community Rating for Profound Medicl (NYSE PROF)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  8 (Vote Outperform)
Underperform Votes:  4 (Vote Underperform)
Total Votes:  12
MarketBeat's community ratings are surveys of what our community members think about Profound Medicl and other stocks. Vote "Outperform" if you believe PROF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PROF will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/28/2020 by MarketBeat.com Staff

Featured Article: Price-Sales Ratio

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel